# N-Acetylcysteine in Patients With Sickle Cell Disease

> **NCT01849016** · PHASE3 · COMPLETED · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 96 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** N-Acetylcysteine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01849016
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2016-07-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01849016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01849016, "N-Acetylcysteine in Patients With Sickle Cell Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01849016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*